Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates
暂无分享,去创建一个
[1] G. Jensen,et al. Cryo-EM structure of a CD4-bound open HIV-1 envelope trimer reveals structural rearrangements of the gp120 V1V2 loop , 2016, Proceedings of the National Academy of Sciences.
[2] Dennis R Burton,et al. Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. , 2016, Annual review of immunology.
[3] Ben Murrell,et al. Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort , 2016, PLoS pathogens.
[4] Jonathan R. McDaniel,et al. Structures of HIV-1-Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design , 2015, Nature Structural &Molecular Biology.
[5] Lynn Morris,et al. New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency , 2015, Journal of Virology.
[6] John P. Moore,et al. Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity , 2015, Journal of Virology.
[7] S. Zolla-Pazner,et al. A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site. , 2015, Molecular immunology.
[8] Hyejin Yoon,et al. CATNAP: a tool to compile, analyze and tally neutralizing antibody panels , 2015, Nucleic Acids Res..
[9] J. Mascola,et al. Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection , 2015, Journal of Virology.
[10] James C Paulson,et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. , 2014, Immunity.
[11] Chaim A. Schramm,et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies , 2014, Nature.
[12] Lili Yang,et al. Passive Immunization against HIV/AIDS by Antibody Gene Transfer , 2014, Viruses.
[13] S. Zolla-Pazner,et al. Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking. , 2014, Virology.
[14] John P. Moore,et al. Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer , 2013, Science.
[15] John P. Moore,et al. Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer , 2013, Science.
[16] H. Liao,et al. Pre-Clinical Development of a Recombinant, Replication-Competent Adenovirus Serotype 4 Vector Vaccine Expressing HIV-1 Envelope 1086 Clade C , 2013, PloS one.
[17] Daphne Koller,et al. The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies , 2013, PLoS pathogens.
[18] J. Mascola,et al. Isolation of human monoclonal antibodies from peripheral blood B cells , 2013, Nature Protocols.
[19] John P. Moore,et al. A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies , 2013, PLoS pathogens.
[20] Ryan McBride,et al. Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans , 2013, PLoS pathogens.
[21] Jeff Tian,et al. A Mechanistic Understanding of Allosteric Immune Escape Pathways in the HIV-1 Envelope Glycoprotein , 2013, PLoS Comput. Biol..
[22] Tongqing Zhou,et al. Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization , 2013, Cell.
[23] Lynn Morris,et al. Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape , 2012, Nature Medicine.
[24] Pham Phung,et al. Sequences in Glycoprotein gp41, the CD4 Binding Site, and the V2 Domain Regulate Sensitivity and Resistance of HIV-1 to Broadly Neutralizing Antibodies , 2012, Journal of Virology.
[25] Kevin W Eliceiri,et al. NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.
[26] Ruth Nduati,et al. Neutralizing Antibody Escape during HIV-1 Mother-to-Child Transmission Involves Conformational Masking of Distal Epitopes in Envelope , 2012, Journal of Virology.
[27] S. Zolla-Pazner,et al. Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals. , 2012, Virology.
[28] Margaret A. Liu. Gene-based passive antibody protection from HIV , 2012, Nature Biotechnology.
[29] D. Montefiori,et al. Elicitation of Neutralizing Antibodies Directed against CD4-Induced Epitope(s) Using a CD4 Mimetic Cross-Linked to a HIV-1 Envelope Glycoprotein , 2012, PloS one.
[30] David Baltimore,et al. Antibody-based Protection Against HIV Infection by Vectored ImmunoProphylaxis , 2011, Nature.
[31] Pham Phung,et al. Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.
[32] Ron Diskin,et al. Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.
[33] S. Zolla-Pazner,et al. Characterization of Structural Features and Diversity of Variable-Region Determinants of Related Quaternary Epitopes Recognized by Human and Rhesus Macaque Monoclonal Antibodies Possessing Unusually Potent Neutralizing Activities , 2011, Journal of Virology.
[34] T. Kepler,et al. Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors , 2011, Journal of Virology.
[35] L. Morris,et al. Potent and Broad Neutralization of HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2 Loop , 2011, Journal of Virology.
[36] S. Rowland-Jones,et al. HIV-1 subtype distribution in the Gambia and the significant presence of CRF49_cpx, a novel circulating recombinant form , 2010, Retrovirology.
[37] R. Abagyan,et al. Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold. , 2010, Virology.
[38] Mario Roederer,et al. Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.
[39] Tongqing Zhou,et al. Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 , 2010, Science.
[40] Timothy Cardozo,et al. Conserved structural elements in the V3 crown of HIV-1 gp120 , 2010, Nature Structural &Molecular Biology.
[41] J. Mascola,et al. Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1 , 2010, Journal of Virology.
[42] D. Burton,et al. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1 , 2010, Proceedings of the National Academy of Sciences.
[43] L. Stamatatos,et al. Quaternary Epitope Specificities of Anti-HIV-1 Neutralizing Antibodies Generated in Rhesus Macaques Infected by the Simian/Human Immunodeficiency Virus SHIVSF162P4 , 2010, Journal of Virology.
[44] Holly Janes,et al. Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies , 2009, Journal of Virology.
[45] Tongqing Zhou,et al. Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120 , 2009, Science.
[46] Pham Phung,et al. Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.
[47] D. Montefiori,et al. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. , 2009, Virology.
[48] Ryan M. O’Connell,et al. Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes. , 2009, Blood.
[49] Lijun Rong,et al. Role of the HIV gp120 Conserved Domain 1 in Processing and Viral Entry* , 2008, Journal of Biological Chemistry.
[50] B. Berkhout,et al. Optimization of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins with V1/V2 Deleted, Using Virus Evolution , 2008, Journal of Virology.
[51] B. Berkhout,et al. Only five of 10 strictly conserved disulfide bonds are essential for folding and eight for function of the HIV-1 envelope glycoprotein. , 2008, Molecular biology of the cell.
[52] M. Caffrey,et al. Role of the HIV gp120 conserved domain 5 in processing and viral entry. , 2008, Biochemistry.
[53] L. Morris,et al. The C3-V4 Region Is a Major Target of Autologous Neutralizing Antibodies in Human Immunodeficiency Virus Type 1 Subtype C Infection , 2007, Journal of Virology.
[54] A. Devico. CD4-induced epitopes in the HIV envelope glycoprotein, gp120. , 2007, Current HIV research.
[55] Mark Connors,et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies , 2007, Nature Medicine.
[56] S Gnanakaran,et al. Clade-Specific Differences between Human Immunodeficiency Virus Type 1 Clades B and C: Diversity and Correlations in C3-V4 Regions of gp120 , 2007, Journal of Virology.
[57] S. Zolla-Pazner,et al. Factors Determining the Breadth and Potency of Neutralization by V3-Specific Human Monoclonal Antibodies Derived from Subjects Infected with Clade A or Clade B Strains of Human Immunodeficiency Virus Type 1 , 2006, Journal of Virology.
[58] S. Zolla-Pazner,et al. Cross-Clade Neutralizing Activity of Human Anti-V3 Monoclonal Antibodies Derived from the Cells of Individuals Infected with Non-B Clades of Human Immunodeficiency Virus Type 1 , 2006, Journal of Virology.
[59] E. Rosenberg,et al. High frequencies of antibody responses to CD4 induced epitopes in HIV infected patients started on HAART during acute infection. , 2006, Human antibodies.
[60] M. Schreiber,et al. N-Glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization , 2006, Medical Microbiology and Immunology.
[61] L. Stamatatos,et al. The V1, V2, and V3 Regions of the Human Immunodeficiency Virus Type 1 Envelope Differentially Affect the Viral Phenotype in an Isolate-Dependent Manner , 2005, Journal of Virology.
[62] S. Zolla-Pazner,et al. The C108g Epitope in the V2 Domain of gp120 Functions as a Potent Neutralization Target When Introduced into Envelope Proteins Derived from Human Immunodeficiency Virus Type 1 Primary Isolates , 2005, Journal of Virology.
[63] L. Stamatatos,et al. Identification of a New Quaternary Neutralizing Epitope on Human Immunodeficiency Virus Type 1 Virus Particles , 2005, Journal of Virology.
[64] S. Zolla-Pazner,et al. Antibodies That Are Cross-Reactive for Human Immunodeficiency Virus Type 1 Clade A and Clade B V3 Domains Are Common in Patient Sera from Cameroon, but Their Neutralization Activity Is Usually Restricted by Epitope Masking , 2005, Journal of Virology.
[65] S. Zolla-Pazner,et al. The V1/V2 Domain of gp120 Is a Global Regulator of the Sensitivity of Primary Human Immunodeficiency Virus Type 1 Isolates to Neutralization by Antibodies Commonly Induced upon Infection , 2004, Journal of Virology.
[66] J. Mascola,et al. The V3 Loop Is Accessible on the Surface of Most Human Immunodeficiency Virus Type 1 Primary Isolates and Serves as a Neutralization Epitope , 2004, Journal of Virology.
[67] D. Dimitrov,et al. Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning. , 2004, Journal of molecular biology.
[68] A. Maerz,et al. Functional Evolution of the HIV-1 Envelope Glycoprotein 120 Association Site of Glycoprotein 41* , 2003, Journal of Biological Chemistry.
[69] Martin A. Nowak,et al. Antibody neutralization and escape by HIV-1 , 2003, Nature.
[70] Peter D. Kwong,et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites , 2002, Nature.
[71] Joseph Sodroski,et al. Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. , 2002, AIDS research and human retroviruses.
[72] M. Caffrey,et al. Solution structure of the HIV gp120 C5 domain. , 2002, European journal of biochemistry.
[73] Abraham Pinter,et al. Human Monoclonal Antibodies Specific for Conformation-Sensitive Epitopes of V3 Neutralize Human Immunodeficiency Virus Type 1 Primary Isolates from Various Clades , 2002, Journal of Virology.
[74] C. Broder,et al. UvA-DARE ( Digital Academic Repository ) Neutralizing antibodies to the HIV-1 envelope glycoproteins , 2009 .
[75] Susan Zolla-Pazner,et al. Truncation of the Cytoplasmic Domain Induces Exposure of Conserved Regions in the Ectodomain of Human Immunodeficiency Virus Type 1 Envelope Protein , 2002, Journal of Virology.
[76] A. Pinter,et al. V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1. , 2001, AIDS research and human retroviruses.
[77] E. Fenyö,et al. Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region. , 2001, AIDS research and human retroviruses.
[78] A. Maerz,et al. Functional Analysis of the Disulfide-Bonded Loop/Chain Reversal Region of Human Immunodeficiency Virus Type 1 gp41 Reveals a Critical Role in gp120-gp41 Association , 2001, Journal of Virology.
[79] W A Hendrickson,et al. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. , 2000, Structure.
[80] L. Stamatatos,et al. V2 Loop Glycosylation of the Human Immunodeficiency Virus Type 1 SF162 Envelope Facilitates Interaction of This Protein with CD4 and CCR5 Receptors and Protects the Virus from Neutralization by Anti-V3 Loop and Anti-CD4 Binding Site Antibodies , 2000, Journal of Virology.
[81] Susan Zolla-Pazner,et al. A Global Neutralization Resistance Phenotype of Human Immunodeficiency Virus Type 1 Is Determined by Distinct Mechanisms Mediating Enhanced Infectivity and Conformational Change of the Envelope Complex , 2000, Journal of Virology.
[82] J. Binley,et al. A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits Is an Antigenic Mimic of the Trimeric Virion-Associated Structure , 2000, Journal of Virology.
[83] G. Quinnan,,et al. Mutations in both gp120 and gp41 Are Responsible for the Broad Neutralization Resistance of Variant Human Immunodeficiency Virus Type 1 MN to Antibodies Directed at V3 and Non-V3 Epitopes , 1998, Journal of Virology.
[84] J. Sodroski,et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.
[85] J. Sodroski,et al. CD4-Induced Conformational Changes in the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein: Consequences for Virus Entry and Neutralization , 1998, Journal of Virology.
[86] J. Sodroski,et al. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein , 1997, Journal of virology.
[87] J. Sodroski,et al. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding , 1995, Journal of virology.
[88] J. McKeating,et al. Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain , 1995, Journal of virology.
[89] R. Connor,et al. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. , 1995, Virology.
[90] J. Sodroski,et al. Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein , 1995, Journal of virology.
[91] S. Zolla-Pazner,et al. Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization. , 1994, Virology.
[92] A. Goudeau,et al. High antigenic cross-reactivity of the V3 consensus sequences of HIV-1 gp120. , 1993, AIDS research and human retroviruses.
[93] A. Pinter,et al. A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates. , 1993, AIDS research and human retroviruses.
[94] Q. Sattentau,et al. Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains , 1993, Journal of virology.
[95] J. Sodroski,et al. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding , 1993, Journal of virology.
[96] A. Shilatifard,et al. gp160 of HIV-I synthesized by persistently infected Molt-3 cells is terminally glycosylated: evidence that cleavage of gp160 occurs subsequent to oligosaccharide processing. , 1991, Archives of biochemistry and biophysics.
[97] J. Sodroski,et al. Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein , 1991, Journal of virology.
[98] J. Davide,et al. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. , 1990, Science.
[99] M. Pawlita,et al. Mutational analysis of the human immunodeficiency virus type 1 env gene product proteolytic cleavage site , 1990, Journal of virology.
[100] S. Zolla-Pazner,et al. Antibodies Targeting the Envelope of HIV-1. , 2015, Microbiology spectrum.
[101] Michel C Nussenzweig,et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. , 2008, Journal of immunological methods.